RaQualia Pharma Inc.
Records under this name other than the patents RaQualia Pharma Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 27 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,776,885 | Benzimidazolone Compounds Having 5-HT4 Receptor Agonistic Activity Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 8,466,166 | Benzimidazole derivatives as selective acid pump inhibitors Formerly held In force · USPTO record | In force | USPTO record | |
| US 7,960,407 | Crystal Forms of an Imidazole Derivative Formerly held In force · High confidence | In force | High confidence | |
| US 9,688,674 | Selective EP4 receptor antagonistic substance for treatment of cancer Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,921,391 | Selective EP4 receptor antagonistic substance for treatment of cancer Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,653,063 | N-substituted saturated heterocyclic sulfone compounds with CB2 receptor agonistic activity Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,980,922 | 5-HT4 Receptor Agonists for the Treatment of Dementia Formerly held In force · High confidence | In force | High confidence | |
| US 9,457,084 | Use of EP4 receptor antagonists in the treatment of IL-23 mediated diseases Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,447,065 | Pharmaceutical Composition Formerly held In force · High confidence | In force | High confidence | |
| US 10,512,635 | Uses of benzimidazole derivative for nocturnal acid breakthrough Formerly held In force · USPTO record | In force | USPTO record |